Quaker BioVentures was founded on the premise that the Mid-Atlantic region is a rich source of life science investment opportunities, and is underserved by venture capital. Historically, the research institutions between New York and North Carolina have received more NIH funding and have generated significantly more life science patents than the institutions on the entire West Coast. Despite this tremendous technology creation, life science companies in the Mid-Atlantic region still receive significantly less venture capital funding than the west coast. Importantly, the area is home to most of the world's large pharmaceutical companies that provide access to spin-out, collaborations, experienced management, and exit opportunities.
Quaker BioVentures remains committed to concentrating its investment efforts in the Mid-Atlantic region. Beginning in 2007, the firm expanded its geographic scope to include opportunistic investments in the Southeast and contiguous areas.
